Ekaterina Vladimirovna Kulikova

Ekaterina Vladimirovna Kulikova

Auto-generated profile, based on publicly available information

Ekaterina Vladimirovna Kulikova

Research Institute of Fundamental and Clinical Immunology

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2015 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
EKEkaterina Vladimirovna Kulikova
Ekaterina Vladimirovna Kulikova
VKVasily Vasilevich Kurilin
Vasily Vasilevich Kurilin
JSJulia Aleksandrovna Shevchenko
Julia Aleksandrovna Shevchenko
IOIrina Aleksandrovna Obleukhova
Irina Aleksandrovna Obleukhova
EKEvgeny Aleksandrovich Khrapov
Evgeny Aleksandrovich Khrapov
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
Significant effort has been devoted to developing effective cancer vaccines based on dendritic cells (DCs) loaded with various tumour antigens, including DNA constructs that carry sequences of tumour‐associated antigens (TAAs). Such vaccines efficiently and selectively activate the T cell immune response. In this study, we describe a method to induce an antitumour immune response in mononuclear cell (MNC) cultures from colorectal cancer patients using DNA‐transfected DCs encoding TAA epitopes of carcinoembryonic antigen, epithelial cell adhesion molecule and mucin 4. DCs were obtained from peripheral blood monocytes of colorectal cancer patients. Magnetic‐assisted transfection was used to deliver the genetic constructs to DCs. To assess the potency of the immune response, the antitumour cytotoxic response was assessed by lymphocyte intracellular perforin and the MNC cytotoxic activity against autologous tumour cells. We showed that polyepitope DNA‐transfected DCs enhanced MNC antitumour activity, increasing tumour cell death and the percentage of perforin‐positive lymphocytes. In addition, DNA‐transfected DCs elicited a cytotoxic response that was as efficient as that of tumour lysate‐loaded DCs. Taken together, the data suggest that it is feasible to induce an antitumour immune response in colorectal MNCs using transfected DCs. Thus, the DNA construct reported in this study may potentially be used in therapeutic and prophylactic DC‐based vaccines.

19 October 2021 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
VKV. V. Kurilin
V. V. Kurilin
EKE. V. Kulikova
E. V. Kulikova
ASA. V. Sokolov
A. V. Sokolov
YKYu. A. Kozhevnikov
Yu. A. Kozhevnikov
DBD. D. Blinova
D. D. Blinova
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
The problem of treatment of oncological diseases is one of the most urgent for modern medicine. Existing treatment approaches are based on a surgical, radiation, chemotherapeutic approach, and the use of immunotherapy methods aimed at markers and / or specific antigens of tumors.Approaches based on the mechanisms of cellular and molecular regulation of a specific antitumor immune response have shown their high efficiency (for example, antibodies against HER2 in breast cancer), but these approaches have a number of side and undesirable effects that limit their application. Considering the central role of the mechanisms of recognition of tumor antigens and their presentation to cytotoxic cells in effective tumor elimination, it is important to search for and develop approaches to restore these mechanisms in cancer pathology. Because maturation, differentiation of dendritic cells and their main function are impaired in oncological diseases, scientific research is underway to obtain mature dendritic cells and restore the natural way of antigen presentation to effector cells.The work carried out limited clinical studies (13 patients with colorectal cancer), a previously developed protocol for obtaining antigen-primed dendritic cells of patients with colorectal cancer and their joint culture with autologous mononuclear cells in vitro. From the peripheral blood of cancer patients, dendritic cells primed with autologous tumor antigens (tumor cell lysate), which were co-cultured with their own mononuclear cells in the presence of immunoregulatory cytokines (IL-12 and IL-18). The resulting cell suspensions were purified from the culture medium and cytokines and used for a course of immunotherapy (weekly, 20-30 million cells intravenously, dropwise), consisting of 3-5 injections. At different periods of immunotherapy (before the start of the course of immunotherapy, 3 months and 6 months after the end of immunotherapy), immunological parameters were assessed in the peripheral blood of patients (immunogram (CD3+, CD3+CD4+, CD3+CD8+, CD19, CD16+CD56+-cells), the relative content of T-regulatory cells (CD4+CD25+FoxP3+-cells), myeloid suppressor cells (CD14+HLA-DR- cells)) and assessed the cytotoxic activity of peripheral blood mononuclear cells of patients against cells of the tumor line of human colorectal cancer (Colo-320).The data obtained showed that in cancer patients, against the background of ongoing immunotherapy, the indicator of the direct cytotoxic test significantly increases, which makes it possible to judge the effective stimulation of the antitumor cellular immune response. This is also indicated by an increase in the relative number of CD16+CD56+-cells (NK-cells) 3 months after immunotherapy. The study of immunosuppressive cells in the blood of cancer patients showed the absence of significant changes in CD14+HLA-DR- -cells and T-regulatory cells.Thus, limited clinical studies of immunotherapy of patients with colorectal cancer based on autologous dendritic cells primed with lysate of autologous tumor cells demonstrated an increase in the antitumor cytotoxic immune response.